MiNK Therapeutics reported its Q1 2026 earnings, highlighting disciplined capital management and strategic clinical advancements. The company ended the quarter with $9.5 million in cash and a net loss of $2.7 million, or $0.57 per share, an improvement from the prior year.
The stock rose 3.52% in premarket trading, reflecting investor optimism about its iNKT cell therapy platform, AGENT-797. Management emphasized capital efficiency and the potential of AGENT-797 in addressing unmet medical needs.
With a cash runway of at least 12 months, MiNK is advancing its randomized ARDS trial and expects to report initial data in H2 2026.
